Deep Track Capital, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001856083
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2025 · 65 positions · Total reported value $3.11B · Top-10 concentration 52.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 59.3% · 18 new · 15 cut · 15 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +27.7% · vs SPY +12.9% · Prev Value $6.12B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2025 13F filing, Deep Track Capital, LP disclosed 65 equity positions with a combined reported value of $3.11B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 52.6% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2025 were GH ($221.17M), IONS ($193.26M), PTGX ($179.40M). By sector, the heaviest allocations are Health Care 78.4%, Other 21.6%. Versus the prior quarter, allocation shifted toward Health Care (+8.0pp) and away from Other (-8.0pp).
Versus the prior quarter, Deep Track Capital, LP opened 18 new positions, trimmed 15 and fully exited 15, a turnover rate of 59.3% of positions. The portfolio's overlap with the prior quarter was 79% of names.
The largest new positions opened in Q2 2025 were AXSM ($83.66M), JBIO ($25.07M), MRUS ($14.46M).
Of the 15 positions fully exited versus the prior quarter, the largest were ITCI ($263.84M), AMGN ($35.22M), EWTX ($30.80M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2025)
- AXSM AXSOME THERAPEUTICS INC. · $83.66M
- JBIO JADE BIOSCIENCES INC · $25.07M
- MRUS MERUS N V · $14.46M
- CDTX CIDARA THERAPEUTICS INC · $12.18M
- CBIO CRESCENT BIOPHARMA INC. · $7.32M
- CNTA CENTESSA PHARMACEUTICALS PLC · $6.57M
Fully Exited (vs previous quarter)
- ITCI INTRA-CELLULAR THERAPIES INC · prev qtr: $263.84M
- AMGN AMGEN INC · prev qtr: $35.22M
- EWTX EDGEWISE THERAPEUTICS INC · prev qtr: $30.80M
- DYN DYNE THERAPEUTICS INC · prev qtr: $20.92M · history
- LKFT LAKEFRONT BIOTHERAPEUTICS NV · prev qtr: $18.62M
- SAGE SAGE THERAPEUTICS INC · prev qtr: $16.21M
- BEAM BEAM THERAPEUTICS INC · prev qtr: $6.17M · history
- RGLS REGULUS THERAPEUTICS INC · prev qtr: $5.71M
Insider Transactions (Form 4)
Latest Deep Track Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-06 | Conversion | Attovia Therapeutics, Inc. | 1,957,138 | — | SEC filing |
Fund Profile
Deep Track Capital, LP is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q2 2026 it reported 66 US equity positions with a combined value of $6.72B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: GREENWICH, CT, United States
- SEC registration: 801-120500 (status: Approved), registered 2021-03-12
- Regulatory AUM (Form ADV): $8.37B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
- Website: deeptrackcapital.com
Portfolio Structure
- 66 positions · $6.72B reported value (Q2 2026)
- Top 10 holdings = 40.5% of reported value
- Largest position: GH (GUARDANT HEALTH INC) at 7.6%
- Average position size: $101.75M
Sector Tilt
- Health Care 95.4%
- (classified holdings cover 95% of value)
Quarterly Activity
- Q2 2026: 18 new, 20 added, 15 reduced, 15 exited
- 13 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
4.25M | $221.17M | 7.11% | Reduce | |
| 2 |
|
4.89M | $193.26M | 6.21% | Add | |
| 3 |
|
3.25M | $179.40M | 5.77% | Add | |
| 4 |
|
17.79M | $176.49M | 5.67% | Hold | |
| 5 |
|
1.75M | $176.12M | 5.66% | Add | |
| 6 |
|
3.04M | $162.35M | 5.22% | Reduce | |
| 7 |
|
9.50M | $152.00M | 4.89% | Hold | |
| 8 |
|
14.29M | $132.65M | 4.26% | Hold | |
| 9 |
|
7.00M | $121.17M | 3.90% | Add | |
| 10 |
|
3.65M | $120.60M | 3.88% | Add | |
| 11 |
|
5.13M | $106.48M | 3.42% | Add | |
| 12 |
|
9.50M | $93.29M | 3.00% | Add | |
| 13 |
|
801.37K | $83.66M | 2.69% | New | |
| 14 |
|
5.38M | $75.22M | 2.42% | Hold | |
| 15 |
|
1.75M | $70.89M | 2.28% | Add | |
| 16 |
|
2.15M | $69.90M | 2.25% | Add | |
| 17 |
|
6.06M | $69.08M | 2.22% | Add | |
| 18 |
|
43.00M | $60.63M | 1.95% | Add | |
| 19 |
|
1.80M | $56.48M | 1.82% | Add | |
| 20 |
|
1.35M | $49.09M | 1.58% | Hold | |
| 21 |
|
3.95M | $48.45M | 1.56% | Add | |
| 22 |
|
700.00K | $45.67M | 1.47% | Hold | |
| 23 |
|
1.35M | $42.26M | 1.36% | Add | |
| 24 |
|
2.23M | $41.60M | 1.34% | Reduce | |
| 25 |
|
2.00M | $40.70M | 1.31% | Hold | |
| 26 |
|
900.00K | $38.86M | 1.25% | Reduce | |
| 27 |
|
16.85M | $38.42M | 1.24% | Reduce | |
| 28 |
|
1.09M | $31.14M | 1.00% | Hold | |
| 29 |
|
7.50M | $27.96M | 0.90% | Add | |
| 30 |
|
1.40M | $27.86M | 0.90% | Hold | |
| 31 |
|
3.48M | $26.62M | 0.86% | Reduce | |
| 32 |
|
2.51M | $25.07M | 0.81% | New | |
| 33 |
|
2.19M | $24.97M | 0.80% | Reduce | |
| 34 |
|
8.83M | $24.73M | 0.80% | Hold | |
| 35 |
|
2.00M | $24.38M | 0.78% | Hold | |
| 36 |
|
2.43M | $22.54M | 0.72% | Add | |
| 37 |
|
1.92M | $21.51M | 0.69% | Add | |
| 38 |
|
4.56M | $16.59M | 0.53% | Hold | |
| 39 |
|
2.50M | $16.23M | 0.52% | Hold | |
| 40 |
|
1.44M | $15.84M | 0.51% | Reduce | |
| 41 |
|
3.44M | $14.67M | 0.47% | Hold | |
| 42 |
|
275.00K | $14.46M | 0.47% | New | |
| 43 |
|
1.53M | $12.84M | 0.41% | Hold | |
| 44 |
|
250.00K | $12.18M | 0.39% | New | |
| 45 |
|
1.20M | $8.36M | 0.27% | Add | |
| 46 |
|
453.69K | $7.32M | 0.23% | New | |
| 47 |
|
500.00K | $6.57M | 0.21% | New | |
| 48 |
|
998.54K | $6.29M | 0.20% | Reduce | |
| 49 |
|
8.59M | $6.14M | 0.20% | Reduce | |
| 50 |
|
751.42K | $6.01M | 0.19% | Reduce | |
FAQ
What did Deep Track Capital, LP buy in 2025-Q2?
In its 2025-Q2 13F filing, Deep Track Capital, LP reported 65 equity positions worth $3.11B in aggregate; its largest disclosed positions were GH ($221.17M), IONS ($193.26M), PTGX ($179.40M).
How large is Deep Track Capital, LP's portfolio?
Deep Track Capital, LP reported $3.11B of long equity holdings across 65 positions as of 2025-Q2. Top-10 holdings account for 52.6% of reported value.
What is Deep Track Capital, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.